Partnerships To Be Precise

Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) examine how the rise of precision medicine is reshaping the role of CDMOs. As drug developers take on increasingly complex, patient-targeted therapies, formulation strategies must evolve to meet the moment. From multi-component ASDs to lipid-based delivery systems, CDMOs must now deliver tailored solutions that match each molecule’s unique properties and the specific needs of diverse patient populations. The article makes a clear case—precision medicine requires precision partnerships.